 Phase liposomal MTP-PE-activated autologous monocytes patients peritoneal carcinomatosis phase autologous monocytes ex vivo patients peritoneal carcinomatosis Blood monocytes leukapheresis counterflow elutriation cells purity Ex vivo activation cells micrograms liposomal monocytes hours hydrophobic culture bags degrees carbon dioxide air activated monocytes peritoneal cavity week consecutive weeks implanted peritoneal infusion system Port-A-Cath Pharmacia Deltec St Paul MN intrapatient dose-escalating schedule monocytes severe adverse reactions Toxicity mild chief acute reactions fever chills abdominal pain None side effects reduction consistent change hemostatic function liver function renal function Significant increases granulocyte counts neopterine acute phase reactants fibrinogen C-reactive protein peripheral blood vitro monocyte activation relapse procoagulant activity monokines tumor necrosis factor-alpha TNF supernatants cultured monocytes Evidence vivo monocyte activation increase monokines peritoneal fluids Kinetic studies autologous monocytes patients monocytes peritoneal cavity days locoregional immunotherapeutic approach view adjuvant therapeutic modality ovarian cancer patients minimal residual intraabdominal disease second-look laparotomy